Role of Diagnostics: NT-proBNP in management of Heart Failure

Wednesday, 16th Nov 2022

6:30 – 7:30 pm AEDT (GMT +11) | 3:30pm – 4:30pm (GMT+8)

View other time zones

This webinar will discuss the latest updates on the management of Heart failure. With new CVD risk assessment tools available, our experts will discuss how they might best be applied in clinical practice.

We look forward to you joining us at the live webinar!


Andrew Sindone

Chair & Speaker

Prof. Andrew Sindone

Director Heart Failure Unit,
Concord Hospital
Head of department of Cardiology,
Ryde Hospital

Read More

J Shaw picture


Prof. Jonathan Shaw

Deputy Director at Melbourne’s Baker Heart and Diabetes Institute

Read More

Christine Burdeniuk


Assoc Prof. Christine Burdeniuk

Associate Professor
Flinders University, SALHN ( South Adelaide Local Health Network)

Read More

Who should attend:

Cardiologist, Endocrinologist, Pathologist, Cardiology advanced Trainees, GP’s, Geriatricians, Basic Physician trainees

Key reasons to attend:

  • To learn about the Latest advances and management of Heart failure.
  • To understand the value of NT-proBNP in clinical use.
  • To know the clinical approach of managing patients with Acute and Chronic Heart Failure.
  • To be aware on the guidelines on usage of NT-proBNP.
  • To hear from APAC Endocrinologist on real world clinical implementation of NT-proBNP in T2DM patients





18:30 – 18:45
Welcome and Latest advances in Heart Failure management in Australia
Prof. Andrew Sindone

18:45 – 19:00
Early NT proBNP testing in Acute and Chronic Heart Failure
A/ Prof. Christine Burdeniuk

19:00 – 19:15
Potential role of NT proBNP as a predictor of Future risk of Heart Failure in Type 2 Diabetes Mellitus of Heart Failure
Prof. Jonathan Shaw

19:15 – 19:30
Q&A and closing

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi